ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2064

An Autoimmune Myositis-Overlap Syndrome Associated With Autoantibodies To Nuclear Pore Complexes ‒ Description and Long-Term Follow-Up Of The Anti-Nup Syndrome

Catherine Isabelle1, Marie-Christine Dabauvalle2, Marvin J. Fritzler3, Ira N. Targoff4, Rose Goldstein5, Yves Troyanov1, Michel Gagné1, Jean-Pierre Raynauld1 and Jean-Luc Senécal1, 1Department of Medicine, Division of Rheumatology, Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, 2University of Würzburg, Würzburg, Germany, 3Medicine, University of Calgary, Calgary, AB, Canada, 4Arthritis and Immunology, Oklahoma Medical Research Foun, Oklahoma City, OK, 5McGill University, Montreal, QC, Canada

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Autoantibodies and myositis

  • Tweet
  • Email
  • Print
Session Information

Title: Muscle Biology, Myositis and Myopathies: Advances in the Epidemiology, Immunology and Therapy of Myositis

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Autoimmune myositis encompasses various myositis-overlap syndromes, each one being identified by the presence of serum marker autoantibodies. We describe a novel myositis-overlap syndrome in four patients characterized by the presence of a unique immunological marker, autoantibodies to nuclear pore complexes.

Methods:

Clinical features and sera were collected from French Canadian patients followed prospectively since 1984 at the Connective Tissue Disease Clinic, Centre Hospitalier de l’Université de Montréal. Reactivity with nuclear pore complexes was identified by indirect immunofluorescence on HEp-2 cells displaying a positive ANA with a distinct punctate peripheral (rim) fluorescent pattern of the nuclear envelope, and confirmed by immunoelectron microscopy. 

Results:

In a cohort of 100 French Canadian patients with autoimmune myositis, sera from 4 (4%) patients displayed a high titer ANA with a fluorescent pattern characteristic of nuclear pore complexes. Clinically, these four patients shared a clinical phenotype characterized by prominent myositis in association with erosive, anti-CCP positive and rheumatoid factor positive arthritis, trigeminal neuropathy, mild interstitial lung disease, Raynaud phenomenon and weight loss. The myositis was typically chronic, relapsing and refractory to corticosteroids alone, but remitted with the addition of a second immunomodulating drug. There was no clinical or laboratory evidence of liver disease. The prognosis was good with 100% long-term survival. The nuclear pore complex fluorescent ANA pattern was not observed in sera from 393 adult patients with systemic sclerosis (n=112), mixed connective tissue disease (n=35), systemic lupus (n=94), rheumatoid arthritis (n=45), or other rheumatic diseases (n=107) nor was it observed in 62 normal adults.

Autoantibodies to nuclear pore complexes were predominantly of IgG isotype. No other IgG autoantibody markers for defined connective tissue diseases or overlap syndromes were present, indicating a selective and highly focused immune response. In three patients, anti-nuclear pore complex autoantibody titers varied in parallel with myositis activity, suggesting a pathogenic link to pathophysiology. The nuclear pore complex proteins, i.e. nucleoporins (nup), recognized by these sera were heterogeneous and included Nup358/RanBP2 (n=2 patients), Nup90 (n=1), and Nup62 (n=1). Taken altogether the data suggested that nup autoantigens themselves drive the anti-nup autoimmune response. Immunogenetically, the four patients shared the DQA1*0501 allele associated with increased susceptibility for autoimmune myositis.

Conclusion:

We report a novel subset of autoimmune myositis in our population of French Canadian patients with connective tissue diseases. This syndrome is recognized by the presence of a unique immunologic marker, autoantibodies to nuclear pore complexes that react with nups, consistent with an “anti-nup syndrome”.


Disclosure:

C. Isabelle,
None;

M. C. Dabauvalle,
None;

M. J. Fritzler,

Inova Diagnostics, Inc.,

5;

I. N. Targoff,
None;

R. Goldstein,
None;

Y. Troyanov,
None;

M. Gagné,
None;

J. P. Raynauld,
None;

J. L. Senécal,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/an-autoimmune-myositis-overlap-syndrome-associated-with-autoantibodies-to-nuclear-pore-complexes-%e2%80%92-description-and-long-term-follow-up-of-the-anti-nup-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology